According to a recent LinkedIn post from C Ray Therapeutics, the company plans to participate in ANZSNM 2026 in Canberra, a key regional conference for nuclear medicine professionals. The post notes that the team will be present at Booth #48 from May 15–17 and is seeking engagement with stakeholders across radiopharmaceutical development, supply, and clinical translation in the Asia-Pacific region.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights specific interest in discussions around Cu-64 and Ac-225 supply partnerships and support for IND-stage CMC questions. This focus suggests C Ray Therapeutics may be positioning itself as a collaborator in theranostic and radiopharmaceutical value chains, which could expand its partnership pipeline and reinforce its role within the emerging CRDMO and broader RDC ecosystems in Asia-Pacific.
For investors, the planned presence at ANZSNM 2026 indicates ongoing business development efforts in a specialized niche of nuclear medicine and radiopharmaceuticals. Increased visibility among clinical and industry stakeholders at such events may support future licensing, supply, or development agreements, potentially enhancing the company’s medium-term commercial opportunities and regional network.